Low-molecular-weight heparins and heparinoids

Owen D Williamson and Alison M. Street
Med J Aust 2003; 178 (8): . || doi: 10.5694/j.1326-5377.2003.tb05269.x
Published online: 21 April 2003

To the Editor: The recent "New Drugs, Old Drugs" review of low molecular weight heparins (LMWH) and heparinoids1 provides a timely reminder of the limitations of studies that support the use of these agents in preventing venous thromboembolism (VTE), particularly in orthopaedic surgery.


  • 1. Eikelboom JW, Hankey GJ. Low molecular weight heparins and heparinoids. Med J Aust 2002; 177: 379-383. <eMJA full text>
  • 2. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-1310.
  • 3. Eriksson BI, Bauer KA, Lassen MR, Turpie AGG. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomized double-blind comparison. Lancet 2002; 359: 1715-1720.
  • 4. Murray DW, Britton AR, Bulstrode CJK. Thromboprophylaxis and death after total hip replacement. J Bone Joint Surg Br 1996; 78: 863-870.
  • 5. Warwick D, Perez J, Vickery C, Bannister G. Does total hip arthroplasty predispose to chronic venous insufficiency? J Arthroplasty 1996; 11: 529-533.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.